Late Breaking Abstract - Protection by budesonide against clinically important deteriorations (CID) in patients with COPD is dependent on blood eosinophil counts (EOS)
主要な著者: | Bafadhel, M, Sing, D, Jenkins, C, Peterson, S, Bengtsson, T, Fageras, M |
---|---|
フォーマット: | Conference item |
出版事項: |
European Respiratory Society
2018
|
類似資料
-
Adding budesonide to formoterol reduces risk of clinically important deteriorations (CID) in moderate to very severe COPD
著者:: Bafadhel, M, 等
出版事項: (2018) -
Modelling peripheral blood eosinophils to identify response to budesonide in COPD: a post-hoc analysis
著者:: Bafadhel, M, 等
出版事項: (2017) -
Investigating blood eosinophil count thresholds in patients with COPD
著者:: Russell, R, 等
出版事項: (2018) -
Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
著者:: Pavord, I, 等
出版事項: (2017) -
Case series of long-term macrolide therapy effect on eosinophil count in COPD
著者:: Asciak, R, 等
出版事項: (2017)